Abstract
We investigated effect of asialoerythropoietin (AEPO), a nonerythrogenic derivative of EPO, on 3 different models of heart failure. A single intraperitoneal injection of doxorubicin (15 mg/kg) induced an established heart failure in mice 2 weeks later, to which AEPO (1500 U/kg, twice a week, for 2 weeks) was administered. Left ventricular dysfunction was attenuated by AEPO. The AEPO-treated heart showed less myocardial fibrosis, inflammatory cell infiltration, and atrophic degeneration of cardiomyocytes accompanying restored expression of GATA-4 and sarcomeric proteins.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
